The Compound Report is an educational resource. Nothing on this site constitutes medical advice or encourages personal use of any compound. Always consult a qualified healthcare provider.

Side by side

Compound comparison

Check interactions →Open as saved/share list

LL-37

Research chemical · Grade C

Goals
healing, beauty, gut, immune
Evidence
2 RCT / 5 animal / 5 in vitro
Routes
injectable-sc, topical, oral
WADA
No
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

KLOW Stack

Research chemical · Grade C

Goals
gut, immune, healing, beauty
Evidence
—
Routes
injectable-sc, topical, oral
WADA
No
FDA
Not approved
Cancer caution
hard-stop
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →

KPV

Research chemical · Grade C

Goals
healing, beauty, gut, immune
Evidence
0 RCT / 4 animal / 3 in vitro
Routes
oral, injectable-sc, topical
WADA
No
FDA
Not approved
Cancer caution
hard-stop
Typical dose
200-500 mcg daily. Oral (capsule or reconstituted oral solution) for gut applications. SubQ injectable for systemic anti-inflammatory effects. Often used in KLOW stack.
Half-life
—
Primary mechanism
NF-κB suppression (primary)
View full report →

Gut Peptide Stack

Research chemical · Grade C

Goals
gut, immune, healing
Evidence
0 RCT / 0 animal / 0 in vitro
Routes
oral
WADA
No
FDA
Not approved
Cancer caution
none
Typical dose
—
Half-life
—
Primary mechanism
Mechanism diagram showing the compound's primary signaling pathway and downstream effects.
View full report →